Gemcitabine and Cisplatin Plus Polymeric Micellar Paclitaxel and Survival in Advanced Biliary Tract Cancer

Does the addition of taxane to standard gemcitabine plus cisplatin chemotherapy in advanced biliary tract cancer improve survival?In this phase 3 randomized clinical trial, 150 patients with previously untreated advanced biliary tract cancers were randomized to receive gemcitabine and cisplatin or gemcitabine and cisplatin plus a polymeric micellar paclitaxel. The addition of the micellar paclitaxel did not improve overall survival or progression-free survival and objective response rates.These results suggest that the addition of the micellar paclitaxel to standard gemcitabine and cisplatin does not improve survival compared with gemcitabine and cisplatin alone in patients with previously untreated advanced biliary tract cancer.

Corresponding Author: Kyu-pyo Kim, MD, PhD, Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, Republic of Korea (kkp1122@amc.seoul.kr).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.